Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature

I Snast, L Atzmony, M Braun, E Hodak… - Journal of the American …, 2017 - Elsevier
Background Patients with psoriasis on biologic therapies and a history of viral hepatitis carry
a risk for reactivation. Objective We evaluated safety of biologic therapies in psoriasis …
被引用次数：96 相关文章

[引用][C] Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature

I Snast, L Atzmony, M Braun, E Hodak… - Journal of the American …, 2017 - cir.nii.ac.jp
Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies:
A retrospective cohort study and systematic review of the literature | CiNii Research CiNii …

Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature.

I Snast, L Atzmony, M Braun, E Hodak… - Journal of the American …, 2017 - europepmc.org
Background Patients with psoriasis on biologic therapies and a history of viral hepatitis carry
a risk for reactivation. Objective We evaluated safety of biologic therapies in psoriasis …

Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature

I Snast, L Atzmony, M Braun… - Journal of the …, 2017 - pubmed.ncbi.nlm.nih.gov
Background Patients with psoriasis on biologic therapies and a history of viral hepatitis carry
a risk for reactivation. Objective We evaluated safety of biologic therapies in psoriasis …

Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature

I Snast, L Atzmony, M Braun, E Hodak… - Journal of the American …, 2017 - jaad.org
Background Patients with psoriasis on biologic therapies and a history of viral hepatitis carry
a risk for reactivation. Objective We evaluated safety of biologic therapies in psoriasis …

Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature.

I Snast, L Atzmony, M Braun, E Hodak, L Pavlovsky - 2017 - cabidigitallibrary.org
Background: Patients with psoriasis on biologic therapies and a history of viral hepatitis
carry a risk for reactivation. Objective: We evaluated safety of biologic therapies in psoriasis …